Levine Cancer Institute
Your multidisciplinary treatment team will be headed by one of our internationally recognized myeloma experts. Leaders in both care and research, our specialists will guide your treatment from start to finish, helping you manage this previously incurable disease with the right chemotherapy regimen or stem cell transplant.
According to a RECENT STUDY PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY, patients with multiple myeloma who received care at higher-volume facilities had a lower risk of death compared with those treated at lower-volume facilities. Today, our specialists follow more than 1,500 active patients – and only about 30,000 cases of multiple myeloma are diagnosed each year in the United States. No matter the stage of your myeloma, we have the experience to help patients just like you manage the impact of the disease with individualized attention.
If a stem cell transplant is called for, we offer the region's first and only adult blood and marrow transplantation unit. Our state-of-the-art facility has performed more than 230 transplants in just the past two years – mostly for multiple myeloma patients. Our program is fully accredited by the Foundation for Accreditation of Cellular Therapy and reports outcomes that place it in the upper echelon of centers.
We are doing this study to learn if the MMprofiler genomic test can help your doctor in making decisions about your treatment.
The INSIGHT MM study is an observational study that may provide a better understanding of current multiple myeloma patients globally, and ways in which they are cared for after they are diagnosed. By participating, you are helping researchers evaluate the effectiveness of interventions for treating diseases in a real-world setting, which can give doctors a better understanding of the health outcomes of complex medical conditions.
This study will test the safety and activity of SGN-CD48A given every 3 weeks to patients with multiple myeloma.
The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 30% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms.
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM).
This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as monotherapy and in combination with dexamethasone.
The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response rate (ORR) and maximum trough concentration.
This study is a phase 1/2 trial of Tinostamustine conditioning and autologous stem cell transplantation for treatment in relapsed / refractory multiple myeloma. The main purpose of this study is to assess the safety and tolerability of Tinostamustine as conditioning in the phase 1 part of the study and the safety, tolerability and efficacy of Tinostamustine in phase 2.
The purpose of the study is to characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2).
This study will look at how subjects with relapsed/refractory multiple myeloma respond to a combination treatment with the following drugs: elotuzumab, carfilzomib, lenalidomide and dexamethasone.
The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma.
This study is a multi-cohort, open-label, multicenter Phase 2 study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1) and in subjects with HR MM having progressed within one year of initial treatment (Cohort 2).
The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for JNJ-64007957 and to characterize the safety and tolerability of JNJ-64007957 at the RP2Ds.
The purpose of this First-in-Human Phase 1 study is to determine during the escalation part if AMG 701 given as weekly short term IV infusions is safe and tolerable followed by a dose expansion part to gain further efficacy and safety experience with AMG 701 in adult subjects with relapsed / refractory multiple myeloma.
The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent MEDI2228 in adult subjects with multiple myeloma who are either transplant ineligible or post autologous stem cell transplant and are relapsed/refractory.
1021 Morehead Medical Drive
Charlotte, NC 28204
Create your account today and get matched to myeloma treatment centers and specialists around the US.
Weekdays 9am - 5pm EST